Tarbox Group Inc. held its position in shares of AbbVie Inc. (NYSE:ABBV) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 53,675 shares of the company’s stock at the end of the first quarter. AbbVie comprises about 1.8% of Tarbox Group Inc.’s holdings, making the stock its 9th largest position. Tarbox Group Inc.’s holdings in AbbVie were worth $3,497,000 as of its most recent filing with the SEC.
Several other institutional investors have also made changes to their positions in ABBV. First Command Financial Services Inc. increased its position in AbbVie by 6.8% in the first quarter. First Command Financial Services Inc. now owns 1,565 shares of the company’s stock valued at $102,000 after buying an additional 99 shares during the last quarter. Patriot Financial Group Insurance Agency LLC purchased a new position in AbbVie during the fourth quarter valued at approximately $137,000. American National Bank increased its position in AbbVie by 13.8% in the first quarter. American National Bank now owns 2,471 shares of the company’s stock valued at $161,000 after buying an additional 299 shares during the last quarter. Cable Hill Partners LLC increased its position in AbbVie by 7.4% in the first quarter. Cable Hill Partners LLC now owns 2,711 shares of the company’s stock valued at $177,000 after buying an additional 186 shares during the last quarter. Finally, Genovese Burford & Brothers Wealth & Retirement Plan Management LLC increased its stake in AbbVie by 5,766.3% in the fourth quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC now owns 178,217 shares of the company’s stock valued at $178,000 after buying an additional 175,179 shares in the last quarter. Hedge funds and other institutional investors own 67.89% of the company’s stock.
AbbVie Inc. (NYSE ABBV) traded up 0.35% on Tuesday, reaching $71.47. The company had a trading volume of 4,353,997 shares. The stock’s 50 day moving average price is $72.07 and its 200-day moving average price is $66.31. The stock has a market capitalization of $113.75 billion, a PE ratio of 17.58 and a beta of 1.50. AbbVie Inc. has a 12-month low of $55.06 and a 12-month high of $75.04. AbbVie also saw some unusual options trading activity on Monday. Stock traders bought 278 put options on the stock. This represents an increase of approximately 121% compared to the average volume of 126 put options.
AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 28th. The company reported $1.42 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.40 by $0.02. The company had revenue of $6.94 billion for the quarter, compared to analyst estimates of $6.93 billion. AbbVie had a net margin of 24.77% and a return on equity of 154.76%. The firm’s revenue was up 7.6% on a year-over-year basis. During the same quarter last year, the business earned $1.26 earnings per share. Equities analysts expect that AbbVie Inc. will post $5.52 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, August 15th. Investors of record on Friday, July 14th will be given a dividend of $0.64 per share. The ex-dividend date is Wednesday, July 12th. This represents a $2.56 annualized dividend and a yield of 3.58%. AbbVie’s dividend payout ratio is presently 62.90%.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.themarketsdaily.com/2017/08/08/tarbox-group-inc-has-3497000-stake-in-abbvie-inc-abbv-updated-updated-updated.html.
Several equities research analysts have issued reports on ABBV shares. BMO Capital Markets restated a “hold” rating and set a $63.00 target price on shares of AbbVie in a research report on Tuesday, April 18th. Leerink Swann set a $71.00 target price on AbbVie and gave the stock a “hold” rating in a research report on Thursday, April 20th. Deutsche Bank AG increased their target price on AbbVie from $64.00 to $65.00 and gave the stock a “hold” rating in a research report on Friday, April 28th. Vetr downgraded AbbVie from a “strong-buy” rating to a “buy” rating and set a $74.98 target price on the stock. in a research report on Thursday, May 4th. Finally, Jefferies Group LLC restated a “buy” rating on shares of AbbVie in a research report on Friday, May 26th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $75.35.
In other AbbVie news, CFO William J. Chase sold 38,300 shares of the stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $65.35, for a total transaction of $2,502,905.00. Following the transaction, the chief financial officer now directly owns 209,043 shares of the company’s stock, valued at $13,660,960.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Chairman Richard A. Gonzalez sold 71,235 shares of the stock in a transaction on Friday, May 19th. The shares were sold at an average price of $65.49, for a total transaction of $4,665,180.15. Following the transaction, the chairman now directly owns 349,462 shares in the company, valued at $22,886,266.38. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 406,895 shares of company stock worth $28,140,423. 0.23% of the stock is owned by company insiders.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.